
Founded in 2007, Genor Biopharma Co. Ltd. (Genor BioPharma, Stock code: 6998.HK) is an innovation-driven biopharma company with a pipeline of therapies covering the world's most prevalent cancer types (breast, lung, and gastrointestinal cancer) and hematological malignancies.
Genor Biopharma strives to build an innovative, platform-oriented and integrated company with innovative drug R&D, preclinical research, clinical development, regulatory, CMC development, and commercial manufacturing.
The company has created a cutting-edge bispecific and multi-specific immune-oncology discovery platform. The industry-leading R&D center has extensive large molecule CMC (Chemistry, Manufacturing, and Controls) development experience. It is capable of developing comprehensive bioprocesses and formulations, and manufacturing preclinical and clinical materials with advanced analytical, quality control, and quality assurance systems for compliance.
The GMP commercial manufacturing facility operates with a highly GMP-compliant production team. The commercial facility employs advanced continuous-flow cell culture technologies for high-yield manufacturing (~20 g/L) as well as internally developed cell culture media for cost-effective production. The site produces Phase III and pivotal trial clinical supplies, executes commercial process validation, and performs commercial manufacturing after product launch.
Beijing office
Yuxi, Yunnan - Principally Phase 3 and commercial manufacturing
Zhangjiang, Shanghai - R&D center, QC/Analytical center, cGMP sample manufacturing
South San Francisco, US - Bi-specific platform


We aspire to become a biopharmaceutical company with global presence, serving patients and society.


Our mission is to become a biopharmaceutical engine in discovery, research, development, manufacturing and commercialization of innovative therapeutics initially for patients in China and gradually for patients globally.